OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments



EN
03/03/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Present at Upcoming March Investor Conference

Oculis to Present at Upcoming March Investor Conference ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference: Leerink Global Healthcare ConferencePresenter: Sylvia Cheung, Chief Financial OfficerPresentation date and time: March 11, 2025 at 3:00pm ETLocation: Miami Beach, FL The Company will be available for one-on-one meetings dur...

21h / 55m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments

March 3, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Or...

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discount...

February 14, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón U...

Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum ZUG, Sviss, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á nýsköpun til að meðhöndla augnsjúkdóma og augntaugasjúkdóma og mæta verulegum óuppfylltum læknisfræðilegum þörfum, greinir í dag frá því að ákvörðun hafi verið tekin um verð og úthlutun almennra hluta í sölutryggðu útboði. Umframeftirspurn var í útboðinu. Seldir voru 5.000.000 almennir hlutir, hver að nafnverði 0,01 CHF, á verðinu 2...

February 14, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Or...

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discount...

February 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch